Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astria Therapeutics, Inc.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of HAE (Type 1 or 2). The following must be met:
1. Documented clinical history consistent with HAE
2. Lab findings consistent with HAE Type 1 or 2
Experienced at least 2 HAE attacks during the Run-In period, as confirmed by an investigator based on meeting the protocol-specified definition of an HAE attack.
You may not be if
Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type 3), idiopathic angioedema, or angioedema associated with urticaria.
Use of therapies prescribed for the prevention of HAE attacks may not be used during the trial or within the below time frames prior to the Run-In Period (adult participants may be on these medications at the time of the Screening Visit, but will need to washout prior to entering the Run-In Period).
1. Tranexamic acid, oral danazol, oral stanazolol, and oral oxandrolone within 3 days prior to Run-In
2. Plasma-derived C1INH for LTP within 14 days prior to Run-In
